HRP20050534A2 - Prevention and treatment of alzheimer's disease - Google Patents

Prevention and treatment of alzheimer's disease

Info

Publication number
HRP20050534A2
HRP20050534A2 HR20050534A HRP20050534A HRP20050534A2 HR P20050534 A2 HRP20050534 A2 HR P20050534A2 HR 20050534 A HR20050534 A HR 20050534A HR P20050534 A HRP20050534 A HR P20050534A HR P20050534 A2 HRP20050534 A2 HR P20050534A2
Authority
HR
Croatia
Prior art keywords
inhibitor
alzheimer
disease
prevention
treatment
Prior art date
Application number
HR20050534A
Other languages
English (en)
Croatian (hr)
Inventor
Canton Thierry
Pradier Laurent
Benavides J�sus
Heuer Hubert
Schaefer Hans-Ludwig
Original Assignee
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.
Publication of HRP20050534A2 publication Critical patent/HRP20050534A2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
HR20050534A 2002-12-12 2003-12-10 Prevention and treatment of alzheimer's disease HRP20050534A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0215722A FR2848452B1 (fr) 2002-12-12 2002-12-12 Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
PCT/FR2003/003654 WO2004062652A1 (fr) 2002-12-12 2003-12-10 Application et traitement de la maladie d'alzheimer

Publications (1)

Publication Number Publication Date
HRP20050534A2 true HRP20050534A2 (en) 2006-11-30

Family

ID=32338722

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20050534A HRP20050534A2 (en) 2002-12-12 2003-12-10 Prevention and treatment of alzheimer's disease

Country Status (22)

Country Link
EP (1) EP1572174A1 (https=)
JP (1) JP2006514063A (https=)
KR (1) KR20050084250A (https=)
CN (1) CN1726016A (https=)
AR (1) AR042354A1 (https=)
AU (1) AU2003296802A1 (https=)
BR (1) BR0317280A (https=)
CA (1) CA2507945A1 (https=)
CO (1) CO5700712A2 (https=)
FR (1) FR2848452B1 (https=)
HR (1) HRP20050534A2 (https=)
MA (1) MA27500A1 (https=)
MX (1) MXPA05005556A (https=)
NO (1) NO20053341L (https=)
NZ (1) NZ540496A (https=)
PE (1) PE20040770A1 (https=)
PL (1) PL377110A1 (https=)
RS (1) RS20050420A (https=)
RU (1) RU2005121909A (https=)
TW (1) TW200503707A (https=)
WO (1) WO2004062652A1 (https=)
ZA (1) ZA200504656B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
AU2004290499C1 (en) 2003-11-03 2011-02-24 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
CA2554809C (en) 2004-02-05 2014-04-29 Probiodrug Ag Novel n-alkyl thiourea- and thioamide-substituted imidazolyl inhibitors of glutaminyl cyclase
JP2008518955A (ja) 2004-11-02 2008-06-05 ノースウェスタン ユニバーシティ ピリダジン化合物および方法
US8158627B2 (en) 2006-04-28 2012-04-17 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
KR101441725B1 (ko) * 2007-05-22 2014-09-18 오츠카 세이야쿠 가부시키가이샤 알츠하이머병 치료를 위한 카르보스티릴 유도체 및 도네페질을 포함하는 치료제
US20130108573A1 (en) 2011-10-28 2013-05-02 Lumena Pharmaceuticals, Inc. Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease
AU2012328526B2 (en) * 2011-10-28 2017-05-25 Shire Human Genetic Therapies, Inc. Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2040996A1 (en) * 1990-05-02 1991-11-03 Robert L. Albright Composition and method for controlling cholesterol
EP0572560B1 (en) * 1991-02-22 2003-01-29 SHAPIRO, Howard, K. Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology
CA2258744A1 (en) * 1996-06-27 1997-12-31 G.D. Searle And Co. Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications
US5985936A (en) * 1997-12-18 1999-11-16 Forbes Medi-Tech, Inc. Method of preventing and delaying onset of Alzheimer's disease and composition therefor
ATE320803T1 (de) * 1998-01-28 2006-04-15 Warner Lambert Co Verfahren zur behandlung von alzheimerschen krankheit
US6080778A (en) * 1998-03-23 2000-06-27 Children's Medical Center Corporation Methods for decreasing beta amyloid protein
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19825804C2 (de) * 1998-06-10 2000-08-24 Aventis Pharma Gmbh 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19845405C2 (de) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
AU2001233299A1 (en) * 2000-02-04 2001-08-14 Esperion Therapeutics Inc. Methods for treating alzheimer's disease
US20020028826A1 (en) * 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
SE0104334D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
TWI329111B (en) * 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents

Also Published As

Publication number Publication date
MXPA05005556A (es) 2005-07-26
BR0317280A (pt) 2005-11-08
PL377110A1 (pl) 2006-01-23
PE20040770A1 (es) 2004-12-10
FR2848452B1 (fr) 2007-04-06
CN1726016A (zh) 2006-01-25
FR2848452A1 (fr) 2004-06-18
WO2004062652A1 (fr) 2004-07-29
EP1572174A1 (fr) 2005-09-14
RU2005121909A (ru) 2006-01-20
RS20050420A (sr) 2007-04-10
ZA200504656B (en) 2006-08-30
JP2006514063A (ja) 2006-04-27
AR042354A1 (es) 2005-06-15
MA27500A1 (fr) 2005-08-01
AU2003296802A1 (en) 2004-08-10
KR20050084250A (ko) 2005-08-26
CO5700712A2 (es) 2006-11-30
NO20053341D0 (no) 2005-07-08
NO20053341L (no) 2005-09-07
NZ540496A (en) 2008-04-30
TW200503707A (en) 2005-02-01
CA2507945A1 (fr) 2004-07-29

Similar Documents

Publication Publication Date Title
ATE299890T1 (de) Inhibitoren von gamma-secretase
BR9914044A (pt) ésteres tetrahidropirido
TNSN01125A1 (fr) Compositions pharmaceutiques comprenant un inhibiteur de cetp et de l'atorvastatine
DE60312017D1 (de) Sulfonderivate zur hemmung von gamma-secretase
ECSP045429A (es) Combinacion de compuestos organicos
UY27972A1 (es) Derivados de hidantoína
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
ATE464287T1 (de) Cyclohexyl-sulphone als gamma-sekretase- inhibitoren
PA8577901A1 (es) Formulacion farmaceutica
ATE416761T1 (de) Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund
EE05556B1 (et) 3-hüdroksü-3-metüülglutarüüli koensüümi kasutamine reduktaasi inhibiitorina ravimi valmistamiseks diabeetilise neuropaatia raviks
ATE350375T1 (de) 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen
PT1115701E (pt) Ureias de arilsulfonanilida
ATE522510T1 (de) Fluoreszierende pyrazin-derivate und verwendungsverfahren dafür bei der überprüfung der nierenfunktion
NO20074941L (no) Anvendelse av diosmetinforbindelser i behandlingen og forebyggingen av trombotiske patologier
PA8583601A1 (es) Derivados de pirrolidona como inhibidores de maob
BR0318278A (pt) compostos de éter aminocicloexìlico e usos dos mesmo
MXPA05009986A (es) Tratamiento de la enfermedad de alzheimer.
ATE482936T1 (de) Als b-sekretase (bace)-hemmer nützliche 2-amino- chinazolinderivate
HUP0301991A2 (hu) IL-18-inhibitorok alkalmazása atheroszklerózis kezelésére és/vagy megelżzésére
AU2003231252A1 (en) Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease
NO20076405L (no) Anvendelse av 24-nor-UDCA
DE602004017326D1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
HRP20050534A2 (en) Prevention and treatment of alzheimer's disease
BR0008382A (pt) Formulação de liberação controlada para tratamento de copd

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20071207

Year of fee payment: 5

OBST Application withdrawn